Can the systemic immune-inflammation index be used to differentiate benign and malignant pathologies before transrectal ultrasound-guided prostate biopsy?
Hematological inflammatory parameters before prostate biopsy are not effective markers for distinguishing between biopsy negative and malignant pathologies. The inflammatory markers SII and PLR can be used as diagnostic tools in high-risk prostate cancer patients but cannot be used as markers for the detection of pathologies in low- and intermediate-risk patients.
Authors
- Veli Mert Yazar (ORCID: https://orcid.org/0000-0001-7885-1401)
- Turgay Kaçan (ORCID: https://orcid.org/0000-0002-7211-8433)
- Buğra Bilge Keseroğlu (ORCID: https://orcid.org/0000-0003-1124-2462)
- Yusuf Gökkurt (ORCID: https://orcid.org/0000-0003-4321-962X)
- Ali Kaan Yıldız (ORCID: https://orcid.org/0000-0002-0999-9872)
- Tolga Karakan (ORCID: https://orcid.org/0000-0002-6694-8369)
- Demirhan Orsan Demir
- Ömer Furkan Erbay (ORCID: https://orcid.org/0000-0002-8117-6176)
Institutions
- Bilkent University (TR)
- Memorial Ankara Hospital (TR)
- Başkent University Hospital (TR)
- Afyonkarahisar Sağlık Bilimleri Üniversitesi
- Afyon Kocatepe University (TR)
Publication Details
- Journal
- BMC Urology
- Published
- 2025-12-04
- DOI
- https://doi.org/10.1186/s12894-025-02011-2
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00